The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
EPI Data Slicer
EPI Data Slicer
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…